450
Participants
Start Date
July 2, 2018
Primary Completion Date
February 6, 2024
Study Completion Date
February 28, 2026
Camrelizumab
Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
Guangzhou Medical University Cancer Hospital, Guangzhou
Panyu central hospital, Guangzhou
Sun Yat-sen University Cancer Center, Guangzhou
First People's Hospital of Foshan, Foshan
Cancer Hospital of Guangxi Medical University, Nanning
Cancer Hospital of Guizhou Medical University, Guiyang
Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Xiangya Hospital Central South University, Changsha
Xijing Hospital, Fourth Military Medical University, Xi’an
West China Hospital, Sichuan University, Chengdu
Sun Yat-sen University
OTHER